Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function

The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long‐acting basal insulin analogue, was evaluated in 5 groups of subjects with varying degrees of renal function based on creatinine clearance: normal renal function (>80 mL/min), mild renal impairment (51–80 mL/min), moderate r...

Descripción completa

Detalles Bibliográficos
Autores principales: Linnebjerg, Helle, Choi, Siak Leng, Lam, Eric Chen Quin, Mace, Kenneth F., Hodgson, Teri S., Sinha, Vikram P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071690/
https://www.ncbi.nlm.nih.gov/pubmed/27163501
http://dx.doi.org/10.1002/cpdd.252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071690/
https://www.ncbi.nlm.nih.gov/pubmed/27163501
http://dx.doi.org/10.1002/cpdd.252

Ejemplares similares